Daratumumab-fihj 120 mg/ML / hyaluronidase-fihj 2000 UNT/ML [Darzalex Faspro]
RxNorm 2375138

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 2375138 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: daratumumab-fihj 120 mg/ML / hyaluronidase-fihj 2000 UNT/ML [Darzalex Faspro].

The following semantic concepts and normalized strings are associated with this clinical entity:

SBDC
Daratumumab-fihj 120 mg/ML / hyaluronidase-fihj 2000 UNT/ML [Darzalex Faspro]
AUI:12408029
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SBDCPrescribable

Semantic Branded Drug Component (SBDC):
Daratumumab-fihj 120 mg/ML / hyaluronidase-fihj 2000 UNT/ML [Darzalex Faspro]
(Atom ID: 12408029)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
daratumumab-fihj 120 MG/ML / hyaluronidase-fihj 2000 UNT/ML [Darzalex Faspro]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2375138
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12408029
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SBDC
Semantic Branded Drug Component (Ingredient + Strength + Brand Name)
Source Code
2375138
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Patient Education

Daratumumab and Hyaluronidase-fihj Injection


Daratumumab and hyaluronidase-fihj injection is used with other medications to treat multiple myeloma (a type of cancer of the bone marrow) in newly diagnosed adults who are unable to receive certain other treatments. Daratumumab and hyaluronidase-fihj injection is also used in combination with other medications to treat multiple myeloma in adults that has returned or has not improved after other treatment(s). This medication is also used alone to treat adults with multiple myeloma who have received at least three lines of treatment with other medications and were not treated successfully. Daratumumab is in a class of medications called monoclonal antibodies. It works by helping the body to slow or stop the growth of cancer cells. Hyaluronidase-fihj is an endoglycosidase. It helps to keep daratumumab in the body longer so that the medication will have a greater effect.
[Learn More]


* Please review the disclaimer below.